Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma
NCT01029418Phase 2Terminated
- Sponsor
- National Cancer Centre Singapore
- Start
- Nov 2009
- Primary completion
- Feb 2014
- Countries
- 1
01
Overview
A Phase 2 trial of selumetinib in hepatocellular carcinoma (HCC), sponsored by National Cancer Centre Singapore. Started Nov 2009; status: terminated.
02
Drugs
selumetinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01029418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01029418.